Teladoc's quarterly revenue has plateaued near $605M to $642M, with year-over-year growth turning negative to -3.4% in the most recent quarter, and operating income has been negative in all ten quarters shown, with an operating margin of -4.6% in 2026Q3.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | -$0.15+31.0% vs -$0.22 | $605M+2.9% vs $588M |
Q3 2026 Jul 29, 2026 | -$0.21+15.9% vs -$0.25 | $607M-1.4% vs $615M |
Q2 2026 Apr 29, 2026 | -$0.36-5.5% vs -$0.34 | $614M+0.5% vs $611M |
Q1 2026 Feb 25, 2026 | -$0.14+26.3% vs -$0.19 | $642M+1.1% vs $635M |
Shrinking revenue hasn't kept Teladoc Health (NYSE:TDOC) from beating estimates on both sales and earnings. Early signs that its BetterHelp mental health business can shift toward insurance-covered care are giving investors a reason to bid the stock up significantly.
Teladoc Health Inc. (NYSE:TDOC) shares are trading higher Thursday after the company reported better-than-expected third-quarter financial results Wednesday after the market closed and raised its 2026 GAAP earnings per share guidance.
Teladoc Health, Inc. (TDOC) Q3 2026 Earnings Call Transcript
Should investors follow Wood's lead with this eVTOL manufacturer?
Benchmark TDOC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Teladoc Health, Inc. (TDOC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.77 | $1.58B | -10.30 | -1.54% | -6.27% | -11.63% | — | |
| $11.91 | $202.57M | -3.56 | -1.98% | -27.03% | -24.11% | — | |
| $26.00 | $5.8B | -42.42 | 59% | -5.51% | -30.03% | — | |
| $32.51 | $6.08B | 43.70 | 13.05% | 21.12% | 14.81% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $37.34 | $1.7B | 38.85 | 6.53% | 3.59% | 3.5% | — |
Teladoc Health, Inc. (TDOC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Teladoc Health, Inc. (TDOC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Jul 29, 2026·SEC
May 21, 2026·SEC
Get notified when TDOC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Teladoc Health, Inc. (TDOC) stock FAQ — growth, dividends, profitability & financials explained
Teladoc Health, Inc. (TDOC) reported $2.47B in revenue over the trailing twelve months. Revenue was $2.53B in fiscal year 2025. That is 12610% more than the $19.9M of fiscal year 2013.
Teladoc Health, Inc. (TDOC) revenue fell by 2.4% over the trailing twelve months, compared with the twelve months before.
No. Teladoc Health, Inc. (TDOC) reported a net loss of $154.8M over the trailing twelve months.
Teladoc Health, Inc. (TDOC) had a return on equity (ROE) of -11.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Teladoc Health, Inc. (TDOC) generated $232.6M in free cash flow over the trailing twelve months.
